Source fact1. CMS ACCESS creates an outcome-aligned Medicare pathway for technology-supported chronic care.
CMS describes ACCESS as a voluntary, 10-year model beginning July 5, 2026, with rolling start dates. It tests an outcome-aligned payment approach in Original Medicare for technology-supported care. CMS maintains an accepted-applicant list and explicitly states that listing does not constitute endorsement or guarantee final participation.
P4L interpretationThe payment pathway may reduce one adoption barrier, but the decision record still needs to distinguish application, acceptance, final participation, delivery, completion, outcomes, and learning. Those milestones answer different institutional questions.
Source fact2. FDA TEMPO links selected digital-health devices to real-world evidence inside ACCESS.
FDA’s participant page listed Cadence Solutions and Dexcom at the August 9 source check. FDA states that the effectiveness of the selected devices for their TEMPO intended uses has not yet been evaluated by the agency. Participants are expected to collect, monitor, and report real-world data, and the pilot operates within specific intended-use and ACCESS conditions.
P4L interpretationSelection is a real program milestone, but it is not an efficacy conclusion or a general authorization for the intended use outside the pilot. The consequential next questions concern safety, real-world evidence, clinical coordination, completion, patient burden, and the path to an appropriate marketing submission.
Source fact3. ARPA-H is making commercialization, workflow, safety, oversight, and trust explicit parts of translation.
ARPA-H announced Neil Wyant as Director of its Office of Commercialization on July 29, 2026. The agency says the office supports Program Managers and awarded performers with market intelligence and guidance around intellectual property, business models, regulatory and reimbursement pathways, and market readiness. A July 23 ARPA-H article on AI and biomedical discovery also highlights data sharing, workflow, safety, oversight, and trust in moving tools toward patient benefit.
P4L interpretationTechnical feasibility is only one transition. A credible pathway also needs an accountable sponsor, data and intellectual-property rights, a regulatory and reimbursement route, workflow fit, adoption ownership, and evidence of real-world value.
What matters next
These developments show payment, regulatory experimentation, real-world evidence, and commercialization infrastructure adapting around technology-supported care. They do not establish that any named device, organization, model, or program has produced a clinical benefit. The useful test is whether each pathway produces proportionate evidence, executable clinical and institutional decisions, completed delivery, acceptable burden, equitable access, and outcomes that can be independently interpreted.
Limits: This note is a public-record synthesis, not a systematic review, product evaluation, investment analysis, clinical recommendation, endorsement, or statement on legal compliance. Program and participant records can change; reverify them before consequential use.